-

Incyte to Report Fourth Quarter and Year-End 2020 Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021.

The schedule for the press release and conference call/webcast is as follows:

• Q4 & YE 2020 Press Release:

February 9, 2021 at 7:00 a.m. ET

• Q4 & YE 2020 Conference Call:

February 9, 2021 at 8:00 a.m. ET

• Domestic Dial-In Number:

877-407-3042

• International Dial-In Number:

201-389-0864

• Conference ID Number:

13715042

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13715042.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for 90 days.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Incyte Contacts

Media

Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com

Christine Chiou
+1 302 274 4773
cchiou@incyte.com

Incyte

NASDAQ:INCY

Release Versions

Contacts

Incyte Contacts

Media

Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com

Christine Chiou
+1 302 274 4773
cchiou@incyte.com

More News From Incyte

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

MORGES, Switzerland--(BUSINESS WIRE)--Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis...

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL...

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

WILMINGTON, Del.--(BUSINESS WIRE)--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET...
Back to Newsroom